AKT1 and breast carcinoma: However, results from recent pre-clinical and clinical studies indicate a modest benefit from PI3K-Akt inhibitors as breast cancer cells acquire resistance due to feedback mechanisms and activation of other oncogenic signaling pathways [2,3].